New drug trial targets Tough-to-Treat breast cancer subtype
NCT ID NCT05831878
Summary
This study is testing whether the drug RC48-ADC can help control advanced breast cancer that has low levels of the HER2 protein. It's for patients who have already tried up to one chemotherapy treatment for their advanced cancer but haven't used this type of drug before. Researchers will measure how well tumors shrink and monitor side effects in about 36 participants.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for ADVANCED BREAST CANCER are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Study contacts
-
Contact
Phone: •••-•••-•••• Email: •••••@•••••
Locations
-
Renji Hospital, School of Medicine, Shanghai Jiaotong University
RECRUITINGShanghai, 200127, China
Contact Phone: •••-•••-•••• Email: •••••@•••••
Conditions
Explore the condition pages connected to this study.